Biological evaluation of 2-methylpyrimidine derivatives as active pan Bcr-Abl inhibitors
作者:DingBiao Zou、YaTao Qiu、ZhengChao Tu、ChenZhong Liao、JinFeng Luo、QingQing Meng、RiSheng Yao、Zheng Li、Sheng Jiang
DOI:10.1007/s11426-013-5011-9
日期:2014.6
We designed a series of 2-methylpyrimidine derivatives as new BCR-ABL inhibitors using scaffold-hopping strategy. These synthetic compounds exhibited significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I mutant. Compound 7u showed very potent kinase inhibitory activities against Bcr-Abl WT, Bcr-Abl E255K, Bcr-Abl Q252H, Bcr-Abl G250E and Bcr-Abl T315I, with IC50 values of 0.13 nM, 0.17 nM, 0.24 nM, 0.19 nM and 0.65 μM, respectively. This compound also displayed anti-proliferation activity against K562 cell line with an IC50 value of 1.1 nM, thus representing a new lead for further optimization.
我们设计了一系列2-甲基吡啶衍生物作为新的BCR-ABL抑制剂,采用了支架跳跃策略。这些合成化合物对广泛的Bcr-Abl突变体表现出显著的抑制作用,包括门控突变体T315I。化合物7u对Bcr-Abl WT、Bcr-Abl E255K、Bcr-Abl Q252H、Bcr-Abl G250E和Bcr-Abl T315I的激酶抑制活性非常强,IC50值分别为0.13 nM、0.17 nM、0.24 nM、0.19 nM和0.65 μM。该化合物还对K562细胞系显示出抗增殖活性,IC50值为1.1 nM,因此代表了进一步优化的新先导化合物。